MOA Life Plus Co (142760) Fair Value & Analysis
Healthcare · KR · Market cap 26.1B KRW
Fair value as of: Jul 7, 2026
From 1 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 3,522 KRW to 370.75 KRW (−89.5%) since Jun 24, 2026. Share price −47.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 374.00 KRW – 2,190 KRW · fair‑value band 244.70 KRW – 463.44 KRW · the 374.00 KRW price screens above the 370.75 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
MOA Life Plus Co (142760) currently trades at 374.00 KRW, while our model-based Fair Value estimate is 370.75 KRW — implying the stock looks roughly 0.9% overvalued today. We read business quality at 20/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 4.7B KRW. Revenue declined 24.7% year over year. It earns a return on equity of -21.6%. Net debt stands at 11.7B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 244.70 KRW (bear case) to 463.44 KRW (bull case); at 374.00 KRW, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -38% fair-value upside — at -1%, 142760 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024. MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MOA Life Plus Co reported revenue of 11.2B KRW in FY2025 versus 101B KRW in FY2021, a compound −42.3%/yr. Reported net income was −13.1B KRW in FY2025.
Is 142760 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MOA Life Plus Co (142760) undervalued?
What is the fair value of 142760?
What is the quality score of 142760?
What is the revenue of MOA Life Plus Co (142760)?
What is the net profit margin of 142760?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.